Are myelodysplastic syndromes ready for venetoclax? Exploring future potential and considerations

Judith S. Hecker; Lavinia Pachzelt; Katharina S. Götze

doi:10.1080/17474086.2021.1968822

Are myelodysplastic syndromes ready for venetoclax? Exploring future potential and considerations

Judith S. Hecker
, Lavinia Pachzelt
, Katharina S. Götze

Klinik und Poliklinik für Innere Medizin III, Hämatologie und Onkologie

Technische Universität München

Publikation: Beitrag in Fachzeitschrift › Artikel › Begutachtung

5 Zitate (Scopus)

Originalsprache	Englisch
Seiten (von - bis)	789-793
Seitenumfang	5
Fachzeitschrift	Expert Review of Hematology
Jahrgang	14
Ausgabenummer	9
DOIs	https://doi.org/10.1080/17474086.2021.1968822
Publikationsstatus	Veröffentlicht - 2021

Zugriff auf Dokument

10.1080/17474086.2021.1968822

Andere Dateien und Links

Verknüpfung zur Publikation in Scopus

Dieses zitieren

@article{ad752597ae12473ba6f7d55a5d01781b,

title = "Are myelodysplastic syndromes ready for venetoclax? Exploring future potential and considerations",

keywords = "Apoptosis, BCL-2, azacitidine, myelodysplastic syndromes, venetoclax",

author = "Hecker, \{Judith S.\} and Lavinia Pachzelt and G{\"o}tze, \{Katharina S.\}",

note = "Funding Information: KS G{\"o}tze received research funding from BMS/Celgene, and has participated in advisory boards for BMS/Celgene and Abbvie. All other authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed. ",

year = "2021",

doi = "10.1080/17474086.2021.1968822",

language = "English",

volume = "14",

pages = "789--793",

journal = "Expert Review of Hematology",

issn = "1747-4086",

publisher = "Taylor and Francis Ltd.",

number = "9",

}

TY - JOUR

T1 - Are myelodysplastic syndromes ready for venetoclax? Exploring future potential and considerations

AU - Hecker, Judith S.

AU - Pachzelt, Lavinia

AU - Götze, Katharina S.

N1 - Funding Information: KS Götze received research funding from BMS/Celgene, and has participated in advisory boards for BMS/Celgene and Abbvie. All other authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.

PY - 2021

Y1 - 2021

KW - Apoptosis

KW - BCL-2

KW - azacitidine

KW - myelodysplastic syndromes

KW - venetoclax

UR - https://www.scopus.com/pages/publications/85113496119

U2 - 10.1080/17474086.2021.1968822

DO - 10.1080/17474086.2021.1968822

M3 - Article

C2 - 34405747

AN - SCOPUS:85113496119

SN - 1747-4086

VL - 14

SP - 789

EP - 793

JO - Expert Review of Hematology

JF - Expert Review of Hematology

IS - 9

ER -